Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2011

View Archived Issues

Selective SYK inhibitors P505-15 and P459-72 show anticancer potential

Anti-HIV-1 activity of aciclovir and potentiation by ribavirin

Tekmira Pharma begins phase I trial of TKM-080301 in solid tumors

New antagonists of melanin-concentrating hormone MCH1 receptor claimed

Apricus Biosciences grants Bracco rights to market Vitaros in Italy

New CGRP receptor antagonists identified by Boehringer Ingelheim

Phase II trial evaluates CK-2017357 in generalized myasthenia gravis

New antagonists of voltage-gated potassium channels claimed by Xention

FDA approves generic version of Doryx

Vascular Biogenics begins phase II trials of VB-111 in glioblastoma and thyroid cancer

Novartis researchers claim novel PI3K and mTOR inhibitors

BioCryst Pharma begins phase IIb trial of BCX-4208 as add-on therapy for gout

Advanced Cell Technology enters stock purchase agreement with Socius

BioSante raises funds for phase III LibiGel program

Phase II data presented on AIC-246 for human cytomegalovirus infection

Cumberland Pharma voluntarily recalls six lots of Acetadote in U.S.

IMMU-114 shows potential for treating GVHD

Lundbeck completes two phase III trials of nalmefene for alcohol dependence

McKesson acquires US Oncology

BL-5010 is efficacious in nonsurgical removal of skin lesions in phase I/II trial

Proteome Sciences and Janssen Pharmaceutica enter into collaboration

MK-2461 is active in model of multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...